Senior Consultants
Dr. Meir (Miki) Pomerantz, M.D.
Senior Clinical Consultant
Dr. Pomeranz is a senior gynecologist and accomplished surgeon, formerly head of Emergency Services at Meir Hospital in Kfar Saba. With extensive experience, Dr. Pomeranz specializes in treating a broad spectrum of obstetric and gynecological conditions, including heavy menstrual bleeding, abdominal pain, fibroids, and endometriosis. He is also a faculty member at the Tel Aviv University School of Medicine. Dr. Pomeranz earned his medical degree from the Technion Institute in 1985 and completed his specialization in Obstetrics and Gynecology at Meir Hospital between 1987 and 1994.
Dr. Moshe Neuman, Ph.D.
Bio Medical Research Design
Ltd. (B.R.D)
Dr. Moshe Neuman is the Founder and Managing Director of Bio Medical Research Design Ltd. (B.R.D), a leading Israeli regulatory affairs consulting firm. B.R.D. specializes in providing expert regulatory advice and comprehensive Contract Research Organization (CRO) services to early-stage Israeli startups in pharmaceuticals, biotechnology, medical devices, and related medical industries. A life scientist by training, Dr. Neuman holds a Ph.D. in Physiology and Pharmacology from Tel Aviv University’s Medical School and has completed advanced studies in regulatory affairs and clinical trial management in both the U.S. and the EU. Dr. Neuman brings extensive research and leadership experience from senior roles at the Life Sciences Research Israel (LSRI) division of the Biological Research Institute and as a founding team member of the Neufeld Cardiac Research Institute at Sheba Medical Center.
Dr. Shimon Amsalem, Ph.D
Chief Scientist at ADAMA Agricultural
Solutions and SpacePharma
A seasoned pharmaceutical and biotech consultant, Dr. Amsalem specializes in formulation development, drug discovery, and drug delivery. Currently serving as Chief Scientist of Delivery Technologies at ADAMA Agricultural Solutions, he is also the Chief Scientific Officer at SpacePharma in Herzliya, Israel, where he advances lab-on-chip nanosatellites for microgravity research. Previously, he held the position of CSO at Marval Pharma Ltd. (Netanya, Israel), focusing on encapsulated iodinated products for CT imaging, and he founded Nextar ChemPharma Solutions Ltd., a contract manufacturing and outsourcing firm for pharmaceutical and analytical services across the biotech, pharma, and medical device industries.
With a Ph.D. in Pharmacology, a Master’s in Pharmaceutical Sciences, and a B.Sc. in Chemistry from the Hebrew University of Jerusalem, Dr Amsalem completed a postdoctoral fellowship at the Walter Reed Army Institute of Research in Washington, D.C. He has worked with several international pharmaceutical companies, including Nova Pharmaceutical Corp. (Baltimore, MD), Alergia Immunologia Abello SA (Madrid, Spain), and Pharmos Corp. (Iselin, NJ, and Rehovot). Over a 25-year career, he has contributed to drug discovery and the development of innovative new chemical entities, working in multidisciplinary R&D environments across all phases—from preclinical research to GMP production—of injectables, ocular, oral, and topical drug products. He has played a significant role in developing 30 new pharmaceutical products, with eight reaching U.S. and European markets, including notable drugs such as Lotemax®, Alrex®, Zylet™, Ultrasome-Q10, Gliadel, Ravimig, Raviten, and the pioneering liposomal product Doxil®.